Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
To screen a dose-dense arm to be used in a future large scale phase III trial. Primary endpoint is safety; secondary endpoints are disease free survival and overall survival. A total of 100 patients were included.
Node Positive Breast Cancer
PROCEDURE: 6 TEC q 3 weeks|PROCEDURE: 4 EC q 2 weeks followed by 4 TXT q 2 weeks|PROCEDURE: 4 TXT q 2 weeks followed by 4 EC q 2 weeks
To screen a dose-dense arm to be used in a future large scale phase III trial. Primary endpoint is safety; secondary endpoints are disease free survival and overall survival. A total of 100 patients were included.